PMID- 33012790
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 0001-4079 (Print)
IS  - 2271-4820 (Electronic)
IS  - 0001-4079 (Linking)
VI  - 204
IP  - 9
DP  - 2020 Dec
TI  - [Novel platelet pharming using human induced pluripotent stem cells].
PG  - 961-970
LID - 10.1016/j.banm.2020.09.040 [doi]
AB  - Ex vivo production of human platelets have been pursued as an alternative measure 
      to resolve limitations in the supply and safety of current platelet transfusion 
      products. To this end, induced pluripotent stem cells (iPSCs) are considered an 
      ideal global source, since they are not only pluripotent and self-renewing, but 
      also are available from basically any person, have relatively few ethical issues, 
      and are easy to manipulate. From human iPSCs, megakaryocyte (MK) lines with 
      robust proliferation capacity have been established by the introduction of 
      specified sets of genes. These expandable MKs are also cryopreservable and thus 
      would be suitable as master cells for good manufacturing practice (GMP) grade 
      production of platelets, assuring availability on demand and safety against 
      blood-borne infections. Meanwhile, developments in bioreactors that physically 
      mimic the in vivo environment and discovery of substances that promote 
      thrombopoiesis have yielded competent platelets with improved efficiency. The 
      derivation of platelets from iPSCs could further resolve transfusion-related 
      alloimmune complications through the manufacturing of autologous products and 
      human leukocyte antigen (HLA)-compatible platelets by manipulation of HLAs and 
      human platelet antigens (HPAs). Considering these key advances in the field, 
      HLA-deleted platelets could become a universal product that is manufactured at 
      industrial level to safely fulfill almost all demands. In this review, we 
      overview the ex vivo production of iPSC-derived platelets towards clinical 
      applications, a production that would revolutionize the blood transfusion system.
CI  - (c) 2020 l'Academie nationale de medecine. Published by Elsevier Masson SAS. All 
      rights reserved.
FAU - Flahou, C
AU  - Flahou C
AD  - Department of Clinical Application, Center for iPS Cell Research and Application, 
      Kyoto University, 53, Kawahara-cho, 606-8507 Shogoin, Sakyo-ku, Kyoto, Japon.
FAU - Sugimoto, N
AU  - Sugimoto N
AD  - Department of Clinical Application, Center for iPS Cell Research and Application, 
      Kyoto University, 53, Kawahara-cho, 606-8507 Shogoin, Sakyo-ku, Kyoto, Japon.
FAU - Eto, K
AU  - Eto K
AD  - Department of Clinical Application, Center for iPS Cell Research and Application, 
      Kyoto University, 53, Kawahara-cho, 606-8507 Shogoin, Sakyo-ku, Kyoto, Japon.
AD  - Department of Regenerative Medicine, Chiba University Graduate School of 
      Medicine, Chiba, Japon.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - La culture de plaquettes a partir de cellules souches pluripotentes induites.
DEP - 20200928
PL  - Netherlands
TA  - Bull Acad Natl Med
JT  - Bulletin de l'Academie nationale de medecine
JID - 7503383
PMC - PMC7521593
OTO - NOTNLM
OT  - Bioreactors
OT  - Induced pluripotent stem cells
OT  - Megakaryocyte
OT  - Platelet transfusion
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
PMCR- 2020/09/28
CRDT- 2020/10/05 06:11
PHST- 2020/03/17 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
PHST- 2020/10/05 06:11 [entrez]
PHST- 2020/09/28 00:00 [pmc-release]
AID - S0001-4079(20)30516-1 [pii]
AID - 10.1016/j.banm.2020.09.040 [doi]
PST - ppublish
SO  - Bull Acad Natl Med. 2020 Dec;204(9):961-970. doi: 10.1016/j.banm.2020.09.040. 
      Epub 2020 Sep 28.